Latest revenue
$110.7M
as of 2026-03-31
Latest net income
$-44.0M
as of 2026-03-31
Net margin
-39.8%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $3.77B
- Enterprise value
- $3.77B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $66.06
- 52-wk low
- $23.30
- Beta
- —
- Shares out
- 62.3M
5-year trend
What this company does
Item 1.Business At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. In fields such as health care, food/agriculture, industrial chemicals/materials and academic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet. We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us. We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing…
AI summary unavailable — showing raw filing excerpt
Generated from TWST's filing dated 2025-11-17
Key risks
Item 1A.Risk Factors Risk Factor Summary Investing in our common stock involves a high degree of risk. You should carefully consider all information in this Form 10-K and in subsequent reports we file with SEC prior to investing in our common stock. These risks are discussed more fully in the section titled “Risk Factors.” These risks and uncertainties include, but are not limited to, the following: •We have incurred net losses in every period to date, and we expect to continue to incur significant losses as we develop our business and may never achieve profitability; •If we are unable to maintain adequate revenue growth or do not successfully manage such growth, our business and growth…
AI summary unavailable — showing raw filing excerpt
Generated from TWST's filing dated 2025-11-17
Profitability
Operating margin
-36.2%
48.7%Net margin
-20.6%
69.1%Return on equity
-16.4%
62.8%Return on assets
-12.1%
64.4%Leverage
Debt / equity
0.36×
19.2%Long-term debt / equity
0.03×
Debt / assets
26.3%
14.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $110.7M | +19.3% | $-44.0M | -11.9% | -39.8% |
Q4 2025 2025-12-31 | $103.7M | +16.9% | $-30.5M | +3.4% | -29.4% |
Q3 2025 2025-09-30 | $99.0M | +16.9% | $-27.1M | +21.7% | -27.4% |
Q2 2025 2025-06-30 | $96.1M | +17.9% | $20.4M | +123.8% | 21.2% |
Q1 2025 2025-03-31 | $92.8M | +23.2% | $-39.3M | +13.5% | -42.4% |
Q4 2024 2024-12-31 | $88.7M | +24.1% | $-31.6M | +26.5% | -35.6% |
Q3 2024 2024-09-30 | $84.7M | — | $-34.7M | — | -40.9% |
Q2 2024 2024-06-30 | $81.5M | +27.8% | $-85.6M | -49.1% | -105.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on TWST — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$20.2M
Net activity
−$20.2M
Distinct insiders
9
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns TWST
Institutional value
$2.14B
Total shares held
46.5M
Distinct holders
164
-78 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Artisan Partners Limited Partnership | 6.4M | $302.6M | +537.6K (+9.2%) | Added |
| 2 | ARK Investment Management LLC | 6.3M | $301.4M | -1.2M (-16.1%) | Trimmed |
| 3 | BlackRock, Inc. | 5.6M | $263.9M | -340.6K (-5.8%) | Trimmed |
| 4 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 5.3M | $250.4M | -684.7K (-11.5%) | Trimmed |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.6M | $125.9M | — | New |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2.6M | $125.4M | — | New |
| 7 | Invesco Ltd. | 2.2M | $103.2M | +881.6K (+68.3%) | Added |
| 8 | Nikko Asset Management Americas, Inc. | 1.5M | $71.1M | -406.7K (-21.4%) | Trimmed |
| 9 | Sumitomo Mitsui Trust Group, Inc. | 1.5M | $71.1M | -406.7K (-21.4%) | Trimmed |
| 10 | BAILLIE GIFFORD & CO | 1.2M | $57.7M | -61.0K (-4.8%) | Trimmed |
| 11 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 824.0K | $39.2M | -349.1K (-29.8%) | Trimmed |
| 12 | DIMENSIONAL FUND ADVISORS LP | 781.6K | $37.1M | -33.8K (-4.1%) | Trimmed |
| 13 | NEW YORK STATE COMMON RETIREMENT FUND | 674.0K | $32.0M | +82.8K (+14.0%) | Added |
| 14 | JENNISON ASSOCIATES LLC | 605.2K | $28.8M | -13.7K (-2.2%) | Trimmed |
| 15 | BNP PARIBAS FINANCIAL MARKETS | 604.0K | $28.7M | +188.4K (+45.3%) | Added |
| 16 | JANE STREET GROUP, LLC | 601.2K | $28.6M | — | New |
| 17 | Allspring Global Investments Holdings, LLC | 455.4K | $22.6M | — | New |
| 18 | CITIGROUP INC | 460.3K | $21.9M | +59.0K (+14.7%) | Added |
| 19 | UBS Group AG | 452.5K | $21.5M | -209.8K (-31.7%) | Trimmed |
| 20 | VANGUARD FIDUCIARY TRUST CO | 423.1K | $20.1M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once TWST's latest filing finishes processing.